NASDAQ:VRNA
Verona Pharma plc Stock News
$15.47
+0.160 (+1.05%)
At Close: Apr 26, 2024
Verona Pharma plc (VRNA) CEO David Zaccardelli on Q1 2021 Results - Earnings Call Transcript
07:17am, Saturday, 01'st May 2021
Verona Pharma plc (VRNA) CEO David Zaccardelli on Q1 2021 Results - Earnings Call Transcript
Verona Pharma Reports First Quarter 2021 Financial Results and Provides Corporate Update
02:00am, Thursday, 29'th Apr 2021
ENHANCE Phase 3 program enrollment continues on track to complete in 2H21
Verona Pharma Reports Results of Pilot Study of pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19
02:00am, Friday, 23'rd Apr 2021
LONDON and RALEIGH, N.C., April 23, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announc
Verona Pharma to Report First Quarter 2021 Financial Results and Provide Corporate Update
02:00am, Wednesday, 21'st Apr 2021
LONDON and RALEIGH, N.C., April 21, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announc
Revisiting Verona Pharmaceuticals
01:52pm, Sunday, 28'th Feb 2021
Today, we take our first new look at Verona Pharmaceuticals in just over a year. The company has advanced its pipeline since then and is well-funded over the near term.
Verona Pharma plc (VRNA) CEO David Zaccardelli on Q4 2020 Results - Earnings Call Transcript
08:44pm, Friday, 26'th Feb 2021
Verona Pharma plc (VRNA) CEO David Zaccardelli on Q4 2020 Results - Earnings Call Transcript
Verona Pharma's pMDI Ensifentrine Shows Improved Lung Function In Mid-Stage COPD Study
05:11am, Tuesday, 02'nd Feb 2021
Verona Pharma PLC (NASDAQ: VRNA) has reported positive data from the Phase 2 study evaluating pressurized metered-dose inhaler formulation (pMDI) of ensifentrine in moderate to severe chronic obstruct
Verona Pharma Secures up to $30 Million Debt Financing from Silicon Valley Bank
02:00am, Monday, 23'rd Nov 2020
Non-dilutive capital to provide further financial flexibility Non-dilutive capital to provide further financial flexibility
Verona Pharma Announces November 2020 Virtual Investor Conference Participation
02:00am, Monday, 09'th Nov 2020
LONDON and RALEIGH, N.C., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announce
Verona Pharma plc (VRNA) CEO David Zaccardelli on Q3 2020 Results - Earnings Call Transcript
09:25am, Sunday, 01'st Nov 2020
Verona Pharma plc (VRNA) CEO David Zaccardelli on Q3 2020 Results - Earnings Call Transcript
Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2020
03:00am, Thursday, 29'th Oct 2020
Initiated ENHANCE Phase 3 clinical trials in COPD
Verona Pharma plc : Update on AIM Delisting
07:01am, Wednesday, 28'th Oct 2020
LONDON and RALEIGH, N.C., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), provides a further update with regards to its intend
